TSC2 and cancer: Various cancer types have been shown to carry druggable targets for mTOR inhibitors, including mutations in MTOR, TSC1, TSC2, NF1, PI3KCA, PIK3CG, STK11, and RHEB [47,48,49,50,51,52,53,54].